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Abstract
Purpose. Recently we showed that the 68-kDa fusion protein derived from the EWS/FLI1 hybrid gene can be speci® cally
detected by Western blotting using a polyclonal antibody to the C-terminal of FLI1 on biopsy material from Ewing’s
sarcoma. The aim of this study was to investigate whether this antibody also could be used for immunocytochemistry and
immunohistochemistry in diagnosis of Ewing’s sarcoma.
Methods. Immunostaining on paraffin-embedded archival material, ® ne-needle aspirates and tumour touch imprints from
Ewing’s sarcomas and primitive neuroectodermal tumours (PNET) for detection of the fusion protein was performed. Most
cases were also analysed byWestern blotting.Tumours of differential diagnostic importance were also included.
Results. Eighty per cent (12/15 cases) of the Ewing tumours exhibited a positive immunoreactivity for the FLI1 antibody.
The signal was mainly localised in the nuclei of the tumour cells, which seems reasonable since EWS/FLI1 is a transcription
factor. The signal was found to be speci® c since it did not appear when the blocking peptide was added to the antibody
solution. Moreover, two other types of small-round cell tumours (i.e. neuroblastoma and alveolar rhabdomyosarcoma) were
negative as well as most normal tissues.
Discussion. Immunostaining of histological and cytological specimens with the FLI1 antibody can be of diagnostic relevance
in Ewing tumours carrying t(11;22).The absence of immunoreactivity in non-Ewing cells is most likely due to a low expres-
sion of the wild-type FLI1 protein.
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Introduction
Morphological diagnosis of Ewing’s sarcoma and
primitive neuroectodermal tumours (PNET), based
on biopsies or ® ne-needle aspirates, is often associ-
ated with severe difficulties.
1± 3 Ewing tumours (ETs)
are recognised as tumour tissue composed of small
round cells, and can be misdiagnosed as other small-
cell tumours like lymphoma, neuroblastoma and rhab-
domyosarcoma, or even benign conditions like
osteomyelitis.
4± 7 ETs are seen mainly in childhood
and in this age group it accounts for approximately
one fourth of all malignancies, or 29 per million
children.
5 Since ET is very primitive, no structural,
enzymatic or cell surface characteristics speci® c for
this entity exist. Diagnosis is therefore frequently made
by excluding other differential diagnostic possibili-
ties.
6 Over the last years several ET-speci® c translo-
cations have been discovered. Ninety per cent of the
ET cases carries the translocation t(11;22)(q24;q12),
5% t(21;22)(q22;q12) and <1% t(7;22)(p22;q12).
8± 12
Recently, two additional chromosomal translocations
in Ewing’s sarcoma have been described, t(17;22) and
t(2;22).
13,14 Analysis of translocations by reverse
transcriptionÐ polymerase chain reaction (RT-PCR) is
a useful option in the diagnosis of ET.
15 A limitation,
however, with RT-PCR in surgical pathology is the
requirement for a strict and rapid handling of fresh
material to avoid degradation of tumour cell mRNA.
The possibility of simply analysing the product of the
EWS/FLI1 fusion gene [i.e. t(11;22)] on a processed
surgical specimen would therefore provide an important
diagnostic tool, especially if suitable material for
RT-PCR is not available. Recently, we applied Western
blotting,using an antibody against the carboxy terminal
of the FLI1 protein (sc-356 or C-19), for detection of
the 68-kDa EWS/FLI1 fusion protein in surgical
biopsies of Ewing’s sarcoma. We could con® rm that
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was only detected in Ewing’s sarcoma cells carrying
t(11;22)(q24;q12).
16The lowest detection level for total
protein was 0.3 m g.
Antibodies against the MIC2 gene product are
commonly used in diagnosis of Ewing’s sarcoma.
17,18
However, several other tumours (including lymphoma
and rhabdomyosarcoma) have been reported to be
immunoreactive to MIC-2 antibodies.
18,19 In the
present study we have investigated whether the FLI1
antibody can be used for detection of EWS/FLI1 using
immunocytochemistry and immunohistochemistry.
Such an application would be very useful in diagnosis
of ET on cytological and paraffin-embedded samples.
Methods
Chemicals
Sc-356 (C-19) (Santa Cruz Biotechnology, Santa
Cruz, USA) is a rabbit polyclonal IgG antibody raised
against a peptide corresponding to amino acids
434± 452 mapping at the carboxy terminus of the
FLI1 protein. The epitope is localised closer to the
C-terminus compared to the ETS binding domain,
which is essential for the binding of the transcription
protein to DNA.
20,21 A blocking peptide (sc-356 P)
(Santa Cruz Biotechnology) was used to con® rm the
speci® city of the FLI-1 antibody. The secondary
antibody used forWestern blotting was goat anti-rabbit
IgG-HRP (sc-2004) (Santa Cruz Biotechnology) and
for immunocytochemistry and immunohistochemistry
we used a biotinylated anti-rabbit IgG (BA-1000)
(Vector Laboratories, Burlingame, USA). The MIC2
gene product was detected by CD99 (DAKO, Glos-
trup, Denmark). All other chemicals, unless not stated
otherwise, were from Sigma Chemicals, St Louis, MO,
USA.
Cell lines
The Ewing’s sarcoma cell line HTB-166 carrying the
t(11;22) (EWS/FLI1) translocation, the breast cancer
cell line MDA 231, the human colonic carcinoma
cell line WiDr, and the human melanoma cell line
SK-MEL-2 were obtained from American Type
Culture Collection, USA. TTC-466, carrying the
t(21,22)(q22;q12) (EWS/ERG) translocation, was
kindly provided by Dr. P. Sorensen (Department of
Pathology, BC Research Institute for Child and Family
Health, Vancouver, Canada). Simian virus-40 trans-
formed human ® broblasts (line 90VAVI) were from
Dr. G. Stein (Department of Molecular, Cellular and
Developmental Biology, University of Colorado,
Boulder, CO, USA). The synovial sarcoma cell line
A-2243 was kindly provided by Dr. S.A. Aaronson
(Mt. Sinai Medical Center, New York, USA). The
human diploid ® broblasts (line GM 08333) were
obtained from Coriell Institute of Medical Research,
NJ, USA and cultured in minimum essential medium
supplemented with 10% (v/v) fetal calf serum, 2 mM
L-glutamine, 1 mM sodium pyruvate, 13 non-essential
amino acids, 0.15 mg/ml benzyl-penicillin and
0.15 mg/ml streptomycin. The cell culture condi-
tions and media for the other cell lines have been
described elsewhere.
16
Tumour material
Fresh-frozen surgical biopsies from clinical cases were
used for Western blotting and/or immunocytochem-
istry.Two ® ne-needle aspirates and nine tumour touch
imprints were put on Superfrost slides (Menzel-
Glaser, Germany) and air-dried for immunostaining.
Sections for immunostainings were obtained from
formalin-® xed paraffin-embedded archival material.
Immunohistochemistry and immunocytochemistry
Immunostaining was performed using the standard
ABC-technique (Vector, Elite Standard Kit. cat.
PK-6100). Paraffin sections were deparaffinised, rehy-
drated and subjected to microwaves (700 W) for 5
min. The endogenous peroxidase activity of the
pre-treated sections and cytological slides was blocked
by hydrogen peroxide (H2O2) dissolved in methanol
(3% H2O2 : methanol, 1:5 by volume) for 30 min.
Sections and slides were then rinsed and incubated
with blocking serum (normal horse serum) for 20
min. Excess serum was drained and the slides were
incubated with the Sc-356 (C-19) antibody at a 1:200
dilution or CD99 at 1:300 dilution. Sc-356 was
incubated overnight at +8Ê C and CD99 was incubated
for 1 h at room temperature. A biotinylated antir-
abbit IgG was used as a secondary antibody and
followed by the ABC-complex.The peroxidase reac-
tion was developed using DAB (Diaminobenzidine
tetrahydrochloride, 0.6 mg/ml with 0.03% H2O2) for
6 min. Counterstaining was performed. Tris-
phosphate buffered saline (pH 7.6) was used for
rinsing between the different steps.
Protein isolation
Total protein was isolated as described elsewhere.
22
Tumour samples were washed twice with phosphate-
buffered saline (PBS) and weighed. Half of each
tumour sample was homogenised in a buffer containing
0.32 M sucrose, 1 mM taurodeoxycholic acid, 2 mM
MgCl2, 1 mM EDTA, 25 mM benzamidine, 1 m g/ml
bacitracin, 2 mM phenylmethylsulphonyl ¯ uoride,
10 m g/ml aprotinin, 10 m g/ml soybean trypsin inhibitor
and 10 m g/ml leupeptin. After a 10-min centrifugation
at 6003 g at 4Ê C the pellet, containing unbroken cells
and cytoskeleton, was discarded.The supernatant was
used for analysis. The concentration of total protein
was measured using the Bio-Rad protein assay (Bio-
Rad, Germany) according to the method of Bradford.
23
26 G. Nilsson et al.Gel electrophoresis
Proteins were dissolved in a sample buffer containing
0.0625 M Tris± HCl (pH 6.8), 20% glycerol, 2%
sodium dodecyl sulphate (SDS), bromophenol blue
and 100-mM dithiothreitol. Samples of variable
protein concentrations were analysed by sodium
dodecyl sulphate± polyacrylamide gel electrophoresis
(SDS± PAGE) with a 4% stacking gel and a 10%
separation gel at 100 V overnight, essentially
according to the protocol of Laemmli.
24 The 53
running buffer was prepared by mixing 15 g Tris
base, 72 g glycine and 5 g SDS in 1 l distilled water,
pH 8.3. A 20 m l SeeBlue Pre-Stained Standard
(NOVEX, San Diego, USA) was run simultane-
ously. Three gel-elecrophoreses were run for each
material, one of which was stained with Coomassie
blue to monitor the quality of the proteins.The two
other gels were used for Western blotting.
Western blotting
After SDS± PAGE the separated proteins were
transferred at 100 V for 3 h to a Hybond-ECL nitro-
cellulose membrane (Amersham Life Science,
Buckinghamshire, UK). The transfer buffer was
prepared by mixing 12.15 gTris base, 56.25 g glycine
and 1 l methanol in 5 l dH2O.The membranes were
subsequently blocked for 1 h at room temperature
with a blocking solution containing 10% (w/v)
skimmed milk powder and 0.3% (v/v) Tween 20 in
PBS, pH 7.5. The membranes were incubated with
the primary antibody C-19 for 1 h with 10% skimmed
milk and 0.3% Tween in PBS.The primary antibody
dilution was 1:500. After two washings, the
membranes were incubated with goat anti-rabbit
IgG-HRP at a 1:500 dilution for 1 h. After washings
the membranes were incubated in ECLWestern blot-
ting detection reagents (Amersham) for 1 min. The
membranes were exposed to Hyper® lm-ECL for 1
min, 5 min or overnight, whereupon detection was
performed.
Results
Fresh-frozen biopsy material from a typical case of
ET was used in the ® rst experiment. Separate samples
were used for Western blotting and for immunos-
taining of ® ne-needle aspirates.Western blotting using
the FLI1 antibody showed a 68-kDa product
corresponding to the EWS/FLI1 fusion protein
(Fig. 1a). As a control, a sample from normal ® brob-
lasts was also analysed.This sample was found to be
negative (Fig 1a). It was con® rmed in a separate
experiment that the 68-kDa band did not appear if
the control peptide (sc-356P) was added to the
antibody solution (data not shown). Figure 1(b) shows
immunostaining with sc-356 (C-19) of the ® ne-
needle aspirate of the same case. There was a clear
positive immunoreactivity of the cells, and this was
mainly con® ned to the cell nuclei. In Fig. 1(c) the
sc-356 immunoreactivity in a ® ne-needle aspirate of
another typical ET case is shown.
In Fig. 2 it is demonstrated that a formalin-® xed
Fig. 1. (a) Detection byWestern blotting of the 68-kDa EWS/FLI1 fusion protein in a ET sample using the FLI1 antibody sc-356
(C-19). (b) Immunostaining with the FLI1 antibody on a ® ne-needle aspirate material from the aforementioned ET sample. (c)
Immunostaining with the FLI1 antibody on cytological sample from another ET case. (3 400)
EWS/FLI1 and immunohistochemistry 27and paraffin-embedded archival specimen of ET was
positively stained by sc-356 (C-19). Even in this case
the immunoreactivity was mainly con® ned to the
nuclei. In order to get this positive signal, antigen
retrieval using microwave treatment was necessary
(see Materials and Methods). As can be seen in the
right panel of Fig. 2, the immunoreactivity was totally
lost if the control peptide (sc-356P) was added
together with the primary antibody during the staining
procedure. In a separate experiment we could confirm
that sc-356P did not decrease the immunoreactivity
of irrelevant antibodies (like MIC-2) (data not
shown).Taken together, these results strongly suggest
that sc-356 (C-19) does not cross-react with other
proteins in the cells.
Figure 3 shows the result from Western blotting
using the sc-356 (C-19) antibody on various types of
ET and non-ET cells and tissues.The purpose of this
experiment was to investigate if there was any detect-
able wild-type FLI1 in the cells. A positive immunos-
taining for FLI1 in the non-ET cells would
considerably decrease the utility of immunostaining
Fig. 2. Immunohistochemistry using the FLI1 antibody sc-356 (C-19) on a paraffin-embedded ET specimen (left panel). Speci® city
on the FLI1 antibody was tested using the peptide against which the FLI1 antibody was raised (right panel).The peptide was added
at concentration exceeding the antibody concentration ten-fold. (3 400)
Fig. 3. Analysis for FLI1 and EWS/FLI1 expression byWestern blotting in various cell types and tissues. ET t(11;22) represented by
HTB-166 cells, ET t(21;22) by TTC-466 cells, syn. sarcoma by A-2243 cells, colonic cancer byWiDr cells, SV40-transformed ® brob-
last by 90VAVI cells, breast cancer by MDA 231 cells, melanoma by SK-MEL-2 cells, and normal ® broblasts by GM 08333. Upper
arrow indicates 68 kDa and lower indicates 51 kDa. High malignant sarcoma refers to malignant ® brous histiocytoma.
28 G. Nilsson et al.in distinguishing between ET and non-ET cells. As
demonstrated all samples analysed, including ET cells
with the t(21;22) translocation and neuroblastoma
tissue, showed no positive signals for FLI1, which has
a molecular weight of 51 kDa.
In Fig. 4(a± d) immunochemistry of four different
cases of ET (with known t(11;22) translocations),
and in Fig. 4(e± f) immunohistochemistry of two cases
of small-round cell non-ET tumours (i.e. neuroblas-
toma and alveolar rhabdomyosarcoma), are shown.
All ET cases were positively stained, whereas the
non-ET cases showed no signi® cant immunoreac-
tivity.Two additional cases of rhabdomyosarcoma and
neuroblastoma were found to be negative for the FLI1
antibody (data not shown). Two cases of non-
Hodgkin’s lymphoma were also negatively stained
(a) (b)
(c) (d)
(e) (f)
Fig. 4. Immunohistochemistry using the FLI1 antibody on four different paraffin-embedded ET specimen (a± d), as well as on a
neuroblastoma (e), and an alveolar rhabdomyosarcoma (f). (3 400)
EWS/FLI1 and immunohistochemistry 29(Table 2 below). However,Western blotting analysis
of two other lymphoma cases (out of four analysed
cases) showed positive signals for wild-type FLI1
(Table 2).
To further evaluate the FLI1 antibody we prepared
tumour touch imprints from nine other fresh frozen
ET biopsies. Immunostaining was performed with
sc-356 (C-19) and CD-99 (MIC-2). The results are
presented in Table 1. Parallel biopsy samples were
analysed for 68-kDa fusion protein using Western
blotting. Unfortunately, the quality of these samples
was not good enough for RT-PCR due to RNA
degradation. However, the isolated proteins were
con® rmed to be intact as assayed by SDS± PAGE and
Coomassie Blue staining.Therefore we could compare
the immunostainings withWestern blotting data. Eight
cases showed a positive 68-kDa signal for the fusion
protein in theWestern blotting analyses, ® ve of which
were also positive in the immunostainings.Two other
immunoimprints could not be evaluated by technical
reasons. The case being negative in Western blotting
(case 6) was also negative for C-19 in the immunoim-
prints (Table 1).This case was, however, positive for
MIC-2. The immunonegativity of case 6 could be
due to an alternative translocation, e.g. t(2;22),
t(7;22), t(17;22) or t(21;22). In only one of the cases
there was a discrepancy between Western blotting
and immunostaining (case 2) (Table 1). This might
be explained by that the EWS/FLI-1 expression was
too low to be detected by immunocytochemistry.We
also tested the immunoreactivity in different types of
normal human tissues, including bone, muscle and
skin. Apart from an intermediate immunoreactivity
in endothelial cells of some vessels, all other tissues
investigated were negative (Table 2). In some cases
in¯ ammatory cells adjacent to in® ltrates to Ewing
tumour tissue showed a slightly positive immunos-
taining (Table 1). However, in four cases of
Table 1. Immunoreactivity of MIC-2 and EWS/FLI-1 in nine additional ET cases*
Case Mic-2 (CD-99) Sc-356 (C-19)
Western blotting
(EWS/FLI-1)
1 ND² ND +
2 + ± +
3 + + +
4 + + +
5 + + +
6 + ± ±
7 + + +
8 ND ND +
9 + + +
*Slides with tumour touch imprints were subjected to immunostaining with sc-356
and CD99 (see Materials and Methods). Cases containing positively stained cells were
then determined microscopically.Two of the cases could not, for technical reasons, be
evaluated by immunocytochemistry.
² Not detectable for technical reasons.
Table 2. Immunoreactivity of C-19 in some tumour and normal tissues*
Tissue Immunoreactivity²
Ewing’s sarcoma (positive control) 3+
Lymphoma 0‡
In¯ ammatory cells adjacent to ET 1+
Osteomyelitis 0
Skeletal muscle 0
Smooth muscle 0
Bone 0
Connective tissue 0
Vessels 0± 2+§
Lung 0
Liver 0
Brain 0
Kidney 0
*One section of formalin-® xed paraffin-embedded material for each tissue was
subjected to immunostaining with C-19 (see Material and Methods).The intensity of
nuclear immunoreactivity was then scored.
² Arbitrary scale 0± 3+ is based on the intensity of immunoreactivity.
‡ Two cases showed no immunoreactivity in immunohistochemical slides.Two out of
four cases showed a clear signal for wild type FLI-1 in Western blotting.
§Some vessels showed positive staining in the endothelial cells.
30 G. Nilsson et al.osteomyelitis the in¯ ammatory cells were negatively
stained (Table 2).
Discussion
The molecular analysis of the t(11;22) rearrange-
ments is likely to be of diagnostic value in Ewing’s
sarcoma and PNET.
25 Moreover, molecular analysis
of tumour-associated gene rearrangements comprises
an important tool in disclosing mechanisms of onco-
genesis. It seems clear that the formation of a
transcription factor from the EWS/FLI1 hybrid gene
is a necessary step in tumourigenesis of ET.
26
Recently, we showed that the 68-kDa EWS/FLI1
fusion protein can be detected by Western blotting
using an antibody (C-19) against the carboxy terminal
of the FLI1 protein.
16
The aim of this study was to investigate whether
immunostaining with C-19 could be used in diagnosis
of ET. Using another FLI1-speci® c antibody, Melot
et al. could detect the EWS/FLI1 fusion protein by
immuno¯ uorescense on cell lines.
27 As shown in the
present study, positive immunostaining of ET was
found in both cytological samples and formalin-fixed
paraffin-embedded surgical specimens.The immuno-
reactivity was mainly localised in the nuclei of the
tumour cells, which seems reasonable since the
EWS/FLI1 protein functions as a transcription
factor.
28 It was con® rmed that the immunoreactivity
was not due to cross-reactivity to other proteins. In
order to perform speci® c diagnosis of ET using immu-
nostaining with C-19 it is of great importance that
the wild-type FLI1 protein is not, or only slightly,
expressed in normal tissue and in tumours that pose
differential diagnostic problem, like neuroblastoma
and rhabdomyosarcoma. In this study we could
con® rm that C-19 immunostainings of neuroblas-
toma and rhabdomyosarcomas were negative.
Furthermore, most normal tissues, with the excep-
tion of endothelial cells and in¯ ammatory cells, were
not immunoreactive. We also tested various types of
non-ET cells and ET cells (including ET carrying
t(21;22)) for the wild-type FLI1 protein using Western
blotting. All of these were also found to be negative.
In contrast, Western blotting analysis of some
lymphoma tissues showed a positive signal
corresponding to wild type FLI1. This result is not
surprising since it is known that heamatopoetic cells
can express FLI1.
29Therefore, despite negative immu-
noreactivity in two lymphoma and four osteomyelitis
cases, we believe that immunostaining with C-19 is
not fully reliable to distinguish ET from lymphoma.
However, the parallel use of alternative markers, like
leukocyte common antigen (LCA), in these cases
could be helpful in this matter.
Taken together, our present results suggest that
immunostaining with FLI1 antibodies can be valu-
able in the diagnosis of Ewing’s sarcoma and PNET,
both on cytological material and surgical biopsies.
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